Nephros, a commercial stage medical device company, develops and sells high-performance liquid purification ultra-filters and an online mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease. Its ultra-filters are primarily used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and/or blood. Nephros was founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize a hemodiafiltration system, an alternative method to hemodialysis. For more information, visit the company’s website at www.nephros.com
Nephros, Inc. (OTCBB: NEPH), a commercial stage medical device company, develops and sells high-performance liquid purification ultra-filters and an online mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease. Its ultra-filters are primarily used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and/or blood. Nephros was founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize a hemodiafiltration system, an alternative method to hemodialysis. For more information, visit the company’s website at www.nephros.com